You are here: Industry Insights > HCV

News List

Integrating Treatment at the Intersection of Opioid Use Disorder and Infectious Disease Epidemics in Medical Settings newsnow
September 04, 2018
A Call for Action After a National Academies of Sciences, Engineering, and Medicine Workshop
AbbVie surprised investors with its hepatitis C success. Will it last? biopharmadive
August 13, 2018
By the time AbbVie brought its first drug for hepatitis C to market, in December 2014, it was already too late.
WHO HCV Guidelines recommends Ascletis' Ravidasvir biospectrumasia
August 10, 2018
Ravidasvir is a next-generation, best-in-class and pan-genotypic HCV NS5A inhibitor with a high genetic barrier to resistance
Ascletis' NDA for its all-oral HCV treatment accepted by CFDA biospectrumasia
August 02, 2018
Ravidasvir in combination with Ganovo (RDV/DNV Regimen) is the first all-oral interferon-free HCV regimen developed by a domestic company in China
Mongolian government sets pace to curb HCV biospectrumasia
June 01, 2018
The project, conducted in collaboration with the Arkhangai Province Health Department in Mongolia has managed to cure and control liver disease caused by viral HCV amongst the population in Arkhangai.
CDA approves Gilead’s chronic hepatitis C virus infection drug biospectrumasia
June 01, 2018
HCV is the fourth-most commonly reported infectious disease in China, with approximately 10 million people infected. HCV genotypes 1, 2, 3 and 6 account for more than 96 percent of all cases.
Dogged by AbbVie's new share-stealing Mavyret, Gilead's hep C forecast comes in far short fiercepharma
February 09, 2018
Gilead Sciences' once-high-flying hepatitis C drugs have come a long way down since their peak sales years, but thanks to new competition from AbbVie, the company's important franchise will have another rough year in 2018.
Gilead Sciences: Investors Are Betting On A Better 2019 forbes
February 08, 2018
The hepatitis C virus. For years, U.S. drug maker Gilead Sciences has been hobbled by weakening sales of drugs for this liver-damaging viral infection.
AbbVie’s Maviret receives Japanese MHLW approval to treat HCV pharmaceufical-technology
September 29, 2017
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved AbbVie’s Maviret (glecaprevir / pibrentasvir) to treat adults with chronic hepatitis C virus (HCV) infection across genotypes 1 to 6 (GT1-6).
FDA approves Vosevi for Hepatitis C worldpharmanews
July 20, 2017
The U.S. Food and Drug Administration has approved Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis.

Previous page 1 2 3 4 Next page